Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Małyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL (2023) A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J 16(2):293–302. https://doi.org/10.1093/ckj/sfac234

Article  CAS  PubMed  Google Scholar 

Alzamora R, Michea L, Marusic ET (2000) Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35(5):1099–1104. https://doi.org/10.1161/01.HYP.35.5.1099

Article  CAS  PubMed  Google Scholar 

Aoun EG, Jimenez VA, Vendruscolo LF, Walter NAR, Barbier E, Ferrulli A, Haass-Koffler CL, Darakjian P, Lee MR, Addolorato G, Heilig M, Hitzemann R, Koob GF, Grant KA, Leggio L (2018) A relationship between the aldosterone-mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans. Mol Psychiatry 23(6):1466–1473. https://doi.org/10.1038/mp.2017.97

Article  CAS  PubMed  Google Scholar 

Arici M, Altun B, Araz M, Atmaca A, Demir T, Ecder T, Guz G, Gogas Yavuz D, Yildiz A, Yilmaz T (2024) The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Front Med (Lausanne) 11:1384454. https://doi.org/10.3389/fmed.2024.1384454

Article  PubMed  PubMed Central  Google Scholar 

Bannan LT, Potter JF, Beevers DG, Saunders JB, Walters JR, Ingram MC (1984) Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin Sci (Lond) 66(6):659–663. https://doi.org/10.1042/cs0660659

Article  CAS  PubMed  Google Scholar 

Brown RW, Chapman KE, Kotelevtsev Y, Yau JLW, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CRW, Seckl JR (1996) Cloning and production of antisera to human placental 11 β-hydroxysteroid dehydrogenase type 2. Biochem J 313(3):1007–1017. https://doi.org/10.1042/bj3131007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao HM, Choo PH, McEwen BS (1989) Glucocorticoid and mineralocorticoid receptor mRNA expression in rat brain. Neuroendocrinology 50(4):365–371. https://doi.org/10.1159/000125250

Article  CAS  PubMed  Google Scholar 

Craft J (2004) Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proceedings (Baylor University. Medical Center) 17(2):217–220. https://doi.org/10.1080/08998280.2004.11927973

Article  PubMed  PubMed Central  Google Scholar 

de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240(2):650–656

Article  PubMed  Google Scholar 

de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W (2000) Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 57(4):1329–1336. https://doi.org/10.1046/j.1523-1755.2000.00971.x

Article  PubMed  Google Scholar 

de la Rosa DA, Ramos-Hernández Z, Weller-Pérez J, Johnson TA, Hager GL (2024) The impact of mineralocorticoid and glucocorticoid receptor interaction on corticosteroid transcriptional outcomes. Mol Cell Endocrinol 594:112389. https://doi.org/10.1016/j.mce.2024.112389

Article  CAS  Google Scholar 

Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A (2023) Finerenone: questions and answers—the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist. J Clin Med 12(12):3992

Article  CAS  PubMed  PubMed Central  Google Scholar 

Döring WK, Herzenstiel MN, Krampe H, Jahn H, Pralle L, Sieg S, Wegerle E, Poser W, Ehrenreich H (2003) Persistent alterations of vasopressin and N-terminal proatrial natriuretic peptide plasma levels in long-term abstinent alcoholics. Alcohol Clin Exp Res 27(5):849–861. https://doi.org/10.1097/01.Alc.0000065433.17403.De

Article  PubMed  Google Scholar 

Dozier BL, Stull CA, Baker EJ, Ford MM, Jensen JP, Finn DA, Grant KA (2019) Chronic ethanol drinking increases during the luteal menstrual cycle phase in rhesus monkeys: implication of progesterone and related neurosteroids. Psychopharmacology 236(6):1817–1828. https://doi.org/10.1007/s00213-019-5168-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fabre LF, Howard PY, Farmer RW (1972) Endocrine abnormalities in male alcoholic subjects. Tex Med 68(10):88–93

PubMed  Google Scholar 

Fabre LF, Farmer RW, Roach MK, Fritchie GE, McIsaac WM (1973) Biochemical and metabolic aspects of alcoholism. Ann N Y Acad Sci 215:346–355. https://doi.org/10.1111/j.1749-6632.1973.tb28288.x

Article  CAS  PubMed  Google Scholar 

Fahlke C, Engel JA, Eriksson CJ, Hård E, Söderpalm B (1994) Involvement of corticosterone in the modulation of ethanol consumption in the rat. Alcohol 11(3):195–202. https://doi.org/10.1016/0741-8329(94)90031-0

Article  CAS  PubMed  Google Scholar 

Fahlke C, Hård E, Eriksson CJ, Engel JA, Hansen S (1995) Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists. Psychopharmacology 117(2):216–224. https://doi.org/10.1007/bf02245190

Article  CAS  PubMed  Google Scholar 

Fahlke C, Hansen S (1999) Effect of local intracerebral corticosterone implants on alcohol intake in the rat. Alcohol Alcohol 34(6):851–861. https://doi.org/10.1093/alcalc/34.6.851

Article  CAS  PubMed  Google Scholar 

Farmer RW, Fabre LF (1975) Some endocrine aspects of alcoholism. Adv Exp Med Biol 56:277–289. https://doi.org/10.1007/978-1-4684-7529-6_14

Article  CAS  PubMed  Google Scholar 

Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF (2022) Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Mol Psychiatry 27(11):4642–4652. https://doi.org/10.1038/s41380-022-01736-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forstenpointner J, Maallo AMS, Elman I, Holmes S, Freeman R, Baron R, Borsook D (2022) The solitary nucleus connectivity to key autonomic regions in humans. Eur J Neurosci 56(2):3938–3966. https://doi.org/10.1111/ejn.15691

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fuller PJ, Young MJ (2005) Mechanisms of mineralocorticoid action. Hypertension 46(6):1227–1235. https://doi.org/10.1161/01.HYP.0000193502.77417.17

Article  CAS  PubMed  Google Scholar 

Geerling JC, Loewy AD (2006) Aldosterone-sensitive neurons in the nucleus of the solitary tract: bidirectional connections with the central nucleus of the amygdala. J Comp Neurol 497(4):646–657. https://doi.org/10.1002/cne.21019

Article  PubMed  PubMed Central  Google Scholar 

Gomez-Sanchez EP (2011) Mineralocorticoid receptors in the brain and cardiovascular regulation: Minority rule? Trends Endocrinol Metab 22(5):179–187. https://doi.org/10.1016/j.tem.2011.02.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomez-Sanchez EP (2016) Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth? J Cardiovasc Pharmacol 67(1):26–38. https://doi.org/10.1097/fjc.0000000000000329

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4(3):965–994. https://doi.org/10.1002/cphy.c130044

Article  PubMed  PubMed Central